Quick Comparison
| Factor | Tesamorelin | CJC-1295 |
|---|---|---|
| Class | Stabilized GHRH analogue | Modified GHRH analog, with or without DAC |
| Half-life | ~11 minutes | With DAC: 5.8-8.1 days. Without DAC: ~30 minutes |
| Approved dosing | 1.28-2mg SubQ, once daily | Not an approved drug; research use: 1-2mg weekly (DAC) or 100mcg 1-3x daily (no-DAC) |
| FDA status | FDA-approved (Egrifta, Egrifta SV, Egrifta WR) | Never FDA-approved; sold as a research chemical |
| Approved indication | Visceral fat reduction in HIV-associated lipodystrophy | None; no approved indication exists |
| Pivotal human trial | 26-week placebo-controlled Phase 3 RCT (Falutz et al.) | Pharmacokinetic study in healthy adults (Teichman et al.), not an efficacy trial |
What Tesamorelin Is
Tesamorelin is a synthetic, stabilized analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland through the same receptor pathway as the body's own GHRH. Unlike most peptides covered on this site, it's a genuine FDA-approved prescription drug, marketed under the brand names Egrifta, Egrifta SV, and Egrifta WR by Theratechnologies, for one specific, narrow indication: reducing excess visceral abdominal fat in HIV-infected adults with lipodystrophy. See the full Tesamorelin reference page for approved dosing by formulation and the off-label research landscape.
What CJC-1295 Is
CJC-1295 is a different synthetic analog of GHRH, sold in two forms with very different half-lives. The DAC (Drug Affinity Complex) version binds to circulating albumin, extending its half-life to roughly a week and supporting once-weekly dosing. The no-DAC version, usually labeled Mod GRF 1-29, clears within about 30 minutes and is dosed multiple times daily. Neither form has ever been evaluated or approved by the FDA; both are sold as research chemicals for laboratory use only. See the full CJC-1295 reference page for dosing ranges and the DAC-versus-no-DAC breakdown.
Half-Life and Dosing: A Counterintuitive Comparison
Tesamorelin's own half-life, about 11 minutes according to its FDA label, is actually shorter than CJC-1295 without DAC (around 30 minutes) and far shorter than CJC-1295 with DAC (5.8-8.1 days). Despite that short half-life, Tesamorelin's approved regimen is once-daily dosing, not the multiple-times-daily pattern a short half-life alone might suggest. That's because the approved dosing schedule was established by the clinical trial program that supported FDA approval, not derived from half-life alone - a single daily pulse of receptor activation was what the pivotal trial actually tested and showed benefit from.
Why this matters: half-life alone doesn't dictate dosing frequency. CJC-1295 with DAC uses its long half-life to justify once-weekly dosing, which makes direct mechanistic sense. Tesamorelin's once-daily schedule exists because that's what its trial program tested and the FDA approved, despite a half-life that's actually shorter than CJC-1295 without DAC. Dosing frequency for an approved drug reflects what was studied, not just pharmacokinetics in isolation.
Human Evidence Compared
This is where the two compounds diverge most sharply. Tesamorelin's approval rests on a 26-week, multicenter, double-blind, placebo-controlled Phase 3 trial in HIV-infected patients, which found a significant, selective reduction in visceral fat versus placebo along with improvements in triglycerides and total cholesterol. That trial, and the regulatory review built on it, is the kind of evidence most research peptides never go through.
CJC-1295's human data comes from a different kind of study: a pharmacokinetic trial in healthy adults that measured half-life and documented sustained elevation of growth hormone and IGF-1 following administration. That's real, peer-reviewed human data, and it's more established than what exists for many research peptides, but it's a mechanism-and-pharmacokinetics study, not a controlled efficacy trial testing CJC-1295 against a placebo for any specific outcome in any patient population the way Tesamorelin's pivotal trial did.
Regulatory Status
Tesamorelin holds FDA approval, the only GHRH analogue with that status, specifically for the HIV-lipodystrophy indication described above. That approval does not extend to general fat loss, athletic performance, or anti-aging use; using it for any of those purposes is off-label, even with the legitimately manufactured branded product. CJC-1295 has no approval history in either form and is not currently on the FDA's 503A or 503B bulk drug substance lists for compounding pharmacies. Products sold as either compound outside a prescription are marketed for laboratory and research use only, not for human consumption, and that framing is a legal distinction rather than a safety endorsement. Consult a qualified healthcare provider before considering any peptide protocol.
Bloodwork to Track
Both compounds act on the same growth-hormone axis, so the relevant marker is the same for either one. IGF-1 is the standard way to track growth-hormone-axis activity, since growth hormone itself is difficult to measure reliably given its pulsatile release. See the peptide bloodwork guide for how IGF-1 fits into a broader baseline panel.
Choosing Between Them
For the one indication Tesamorelin is actually approved for, visceral fat reduction in HIV-associated lipodystrophy, it isn't really a choice between the two: Tesamorelin is the only one of these compounds with FDA approval and trial evidence for that specific use. Outside that narrow indication, both are functioning as research-use GHRH-pathway compounds, and the practical difference comes down to half-life and dosing convenience rather than one having a validated edge over the other for general use. For context on how CJC-1295 compares to a third GHRH analogue with its own approval history, see CJC-1295 vs Sermorelin. BioStackIQ's Rate My Stack can help evaluate how either compound fits into a broader protocol.